Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6263925 | 0.74 | LMNA (0.38) | OPRM1OPRD1OPRK1OPRL1 | |
| Indanorex SCHEMBL162653 | 0.73 | DPP8 (0.38) | OPRM1OPRD1OPRK1OPRL1HTR2A | |
| SCHEMBL4644536 | 0.72 | HTR2A (0.37) | HTR2AHDAC9L3MBTL1 | |
| SCHEMBL26605092 | 0.71 | HTR2A (0.36) | HTR2AL3MBTL1 | |
| SCHEMBL8162156 | 0.71 | HDAC9 (0.39) | HDAC9 | |
| SCHEMBL27498922 | 0.70 | HTR2A (0.35) | HTR2AHDAC9L3MBTL1 | |
| Methane SCHEMBL29046923 | 0.70 | HTR2A (0.35) | HTR2AHDAC9L3MBTL1 | |
| Methyl Alcohol SCHEMBL28424110 | 0.70 | HTR2A (0.35) | HTR2AHDAC9L3MBTL1 | |
| SCHEMBL26605081 | 0.70 | HDAC9 (0.41) | OPRK1HDAC9NOTUML3MBTL1 | |
| SCHEMBL14707572 | 0.69 | SMN1; SMN2 (0.34) | OPRM1OPRD1OPRL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148409-A1 | CRYSTAL OF SALT OF NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | UBE CORPORATION (JP) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148409-A1 | CRYSTAL OF SALT OF NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRD1 2/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.